Market Cap (In SEK)
282.12 Million
Revenue (In SEK)
53 Thousand
Net Income (In SEK)
-37.17 Million
Avg. Volume
8164.00
- Currency
- SEK
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 5.5-18.4
- PE
- -
- EPS
- -
- Beta Value
- 0.151
- ISIN
- SE0015660899
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Ola Sandborgh
- Employee Count
- -
- Website
- https://www.lipum.se
- Ipo Date
- 2021-04-22
- Details
- Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of pediatric rheumatism and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116. The company was founded in 2010 and is headquartered in Umeå, Sweden.
More Stocks
-
6134
-
NEV
-
ABHBYAlfen N.V.
ABHBY
-
195ARICECURRY INC
195A
-
1023
-
SOLReneSola Ltd
SOL
-
FSUGY
-
NIPNFNEC Corporation
NIPNF